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INTERFERON ALFA-2b ALONE OR IN COMBINATION WITH RIBAVIRIN
AS INITIAL TREATMENT FOR CHRONIC HEPATITIS C
JOHN G. MCHUTCHISON, M.D., STUART C. GORDON, M.D., EUGENE R. SCHIFF, M.D., MITCHELL L. SHIFFMAN, M.D.,
WILLIAM M. LEE, M.D., VINOD K. RUSTGI, M.D., ZACHARY D. GOODMAN, M.D., PH.D., MEI-HSIU LING, PH.D.,
SUSANNAH CORT, M.D., AND JANICE K. ALBRECHT, PH.D., FOR THE HEPATITIS INTERVENTIONAL THERAPY GROUP*

ABSTRACT
Background Only 15 to 20 percent of patients
with chronic hepatitis C have a sustained virologic
response to interferon therapy. We compared the efficacy and safety of recombinant interferon alfa-2b
alone with those of a combination of interferon alfa2b and ribavirin for the initial treatment of patients
with chronic hepatitis C.
Methods We randomly assigned 912 patients with
chronic hepatitis C to receive standard-dose interferon alfa-2b alone or in combination with ribavirin
(1000 or 1200 mg orally per day, depending on body
weight) for 24 or 48 weeks. Efficacy was assessed by
measurements of serum hepatitis C virus (HCV) RNA
and serum aminotransferases and by liver biopsy.
Results The rate of sustained virologic response
(defined as an undetectable serum HCV RNA level 24
weeks after treatment was completed) was higher
among patients who received combination therapy
for either 24 weeks (70 of 228 patients, 31 percent)
or 48 weeks (87 of 228 patients, 38 percent) than
among patients who received interferon alone for
either 24 weeks (13 of 231 patients, 6 percent) or 48
weeks (29 of 225 patients, 13 percent) (P<0.001 for
the comparison of interferon alone with both 24 weeks
and 48 weeks of combination treatment). Among patients with HCV genotype 1 infection, the best response occurred in those who were treated for 48
weeks with interferon and ribavirin. Histologic improvement was more common in patients who were
treated with combination therapy for either 24 weeks
(57 percent) or 48 weeks (61 percent) than in those
who were treated with interferon alone for either 24
weeks (44 percent) or 48 weeks (41 percent). The drug
doses had to be reduced and treatment discontinued
more often in patients who were treated with combination therapy.
Conclusions In patients with chronic hepatitis C,
initial therapy with interferon and ribavirin was more
effective than treatment with interferon alone. (N Engl
J Med 1998;339:1485-92.)
©1998, Massachusetts Medical Society.

C

HRONIC hepatitis C infection is now recognized as an important health care problem.1 Nearly 4 million Americans are estimated to be infected, and cirrhosis will
eventually develop in at least 15 to 20 percent of
them.2-5 In the United States, infection with hepatitis
C virus (HCV) is a leading cause of chronic liver disease and the most common indication for liver transplantation.1,6
Until recently, interferon alfa was the only therapy available for patients with chronic hepatitis C.
However, after 48 weeks of treatment, serum HCV
RNA levels are undetectable in only 15 to 20 percent of patients.7-12 Pilot studies of patients who have
relapsed and of previously untreated patients suggest
that combining interferon with ribavirin is more effective than using interferon alone,13,14 and in a
small, placebo-controlled study of previously untreated patients, treatment with interferon and ribavirin for six months was more effective than interferon alone.15
The aims of this study were to compare the safety
and efficacy of interferon alone and in combination
with ribavirin for the initial treatment of chronic
hepatitis C and to determine the optimal duration
of combination therapy.

From the Division of Gastroenterology–Hepatology, Scripps Clinic
and Research Foundation, La Jolla, Calif. (J.G.M.); William Beaumont
Hospital, Royal Oak, Mich. (S.C.G.); University of Miami, Miami (E.R.S.);
Medical College of Virginia, Richmond (M.L.S.); University of Texas
Southwestern Medical Center, Dallas (W.M.L.); Georgetown University,
Washington, D.C. (V.K.R.); Armed Forces Institute of Pathology, Washington, D.C. (Z.D.G.); and Schering-Plough Research Institute, Kenilworth, N.J. (M.-H.L., S.C., J.K.A.). Address reprint requests to Dr.
McHutchison at Scripps Clinic and Research Foundation, Division of Gastroenterology–Hepatology (203N), 10666 N. Torrey Pines Rd., La Jolla,
CA 92037.
*The other members of the Hepatitis Interventional Therapy Group are
listed in the Appendix.
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METHODS
Selection of Patients
Adult patients were eligible for the study if they were seropositive for HCV RNA on testing with the polymerase chain reaction,
had undergone a liver biopsy within one year before entry whose
results were consistent with a diagnosis of chronic hepatitis, and had
had elevated serum alanine aminotransferase values (more than
the upper limit of normal values) for at least six months. Patients
with decompensated cirrhosis,16 serum alpha-fetoprotein concentrations of more than 50 ng per milliliter, anemia (hemoglobin concentration, less than 12 g per deciliter in women and less than 13 g
per deciliter in men), human immunodeficiency virus infection,
psychiatric conditions, seizure disorders, cardiovascular disease, hemophilia, poorly controlled diabetes mellitus, or autoimmune diseases were excluded, as were those who had undergone organ transplantation and those who were unable to practice contraception.
Study Design and Organization
This double-blind, placebo-controlled trial was conducted at
44 centers in the United States. The study was approved by the
institutional review board at each center, and all the patients provided written informed consent. We screened 1337 patients, of
whom 404 did not meet the inclusion criteria. The remaining
933 patients were randomly assigned to one of four treatment
groups, which were balanced for the presence or absence of cirrhosis, pretreatment serum HCV RNA level, and HCV genotype.
The analysis was based on the 912 patients who received at least

one dose of medicine (21 patients were randomly assigned to a
treatment group but did not receive therapy: 13 did not wish to
continue, 5 did not meet the entry criteria, and 3 had adverse
events before the initiation of therapy). Enrollment began in
April 1996, and the trial was completed in March 1998.
The patients were randomly assigned to a treatment group as
follows: recombinant interferon alfa-2b (Intron A, ScheringPlough, Kenilworth, N.J.) plus placebo for 24 weeks in the case
of 231 patients and for 48 weeks in the case of 225 patients, and
the combination of interferon alfa-2b and ribavirin (Rebetron,
Schering-Plough) for 24 weeks in the case of 228 patients and for
48 weeks in the case of 228 patients. Interferon alfa-2b was given
subcutaneously in a dose of 3 million units three times per week,
and ribavirin (or matched placebo) was administered orally twice
a day at a total daily dose of 1000 mg for patients who weighed
75 kg or less and 1200 mg for those who weighed more than
75 kg. Both drugs were started and stopped at the same time.
The severity of adverse events was graded as mild, moderate,
severe, or life-threatening17; therapy was discontinued after lifethreatening events. For severe adverse events other than anemia,
the dose of interferon alfa-2b was reduced to 1.5 million units
three times a week and the dose of ribavirin was reduced to 600 mg
per day. The full dose could be resumed after the event or discontinued if the effect persisted. The dose of ribavirin was reduced to 600 mg per day in patients whose hemoglobin concentrations fell below 10 g per deciliter, and it was discontinued if
the concentration fell below 8.5 g per deciliter.
The patients were evaluated as outpatients at weeks 1, 2, 4, 6,
and 8 and then every 4 weeks during treatment and 4, 8, 12, and

TABLE 1. BASE-LINE CHARACTERISTICS

CHARACTERISTIC

Age — yr
Sex — M/F
Weight — kg
Serum alanine aminotransferase —
no. of times upper limit of normal
Serum aspartate aminotransferase —
no. of times upper limit of normal
Serum HCV RNA
No. of copies/ml — ¬10¡6
>2¬106 copies/ml — no. (%)
Estimated duration of infection — yr†
Source or type of infection — no. (%)
Transfusion
Intravenous drug use
Sporadic or unknown
Genotype — no. (%)
1
2
3
Other
Knodell score‡
Cirrhosis — no. (%)
Bridging fibrosis — no. (%)

OF THE

INTERFERON

PATIENTS.*

INTERFERON

AND

RIBAVIRIN

24 WK
(N=231)

48 WK
(N=225)

24 WK
(N=228)

48 WK
(N=228)

45±7
154/77
83.9±17.0
4.0±2.9

44±8
150/75
83.3±16.3
3.7±2.5

44±8
148/80
83.7±18.1
4.1±2.8

44±8
152/76
80.8±17.9
3.7±2.3

2.9±2.3

2.7±1.7

2.9±2.2

2.7±1.7

5.0±5.0
157 (68)
18.5±9.1

4.8±4.6
162 (72)
18.8±9.5

5.1±5.8
166 (73)
18.9±9.8

5.7±7.5
152 (67)
19.6±9.6

41 (18)
124 (54)
66 (29)

54 (24)
115 (51)
56 (25)

55 (24)
106 (46)
67 (29)

49 (21)
127 (56)
52 (23)

167 (72)
38 (16)
24 (10)
2 (1)
7.4±2.7
15 (6)
50 (22)

162 (72)
43 (19)
19 (8)
1 (0.4)
7.6±2.6
10 (4)
61 (27)

164 (72)
29 (13)
28 (12)
7 (3)
7.5±2.5
9 (4)
50 (22)

166 (73)
37 (16)
23 (10)
2 (1)
7.3±2.8
15 (7)
40 (18)

*Plus–minus values are means ±SD. Because of rounding, percentages may not total 100. None
of the differences among the groups were significant.
†The duration of infection was estimated from the date of transfusion or initial exposure to other
parenteral sources, and it could not be calculated for patients with sporadic infection or those in
whom the source of infection was unknown.
‡Scores could range from 0 to 18, with higher scores indicating more severe abnormalities.
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24 weeks after therapy. Biochemical and hematologic testing was
performed by a central laboratory. Serum HCV RNA levels were
determined before treatment; during treatment at weeks 4, 12,
and 24; at 36 and 48 weeks in the patients who were treated for
48 weeks; and after therapy at weeks 12 and 24. Serum HCV RNA
was measured by a reverse-transcription–polymerase-chain-reaction
assay with a sensitivity of 100 copies per milliliter (National Genetics Institute, Los Angeles).18 HCV genotyping was performed
as previously described.19 Liver biopsy was performed 24 weeks
after the end of treatment, and the specimens were analyzed by a
single pathologist who was unaware of the patients’ identification,
treatment regimen, and response and of the timing of the biopsy
in relation to treatment.

Statistical Analysis

Assessment of Efficacy

Characteristics of the Patients

The primary end point was a sustained virologic response, defined as the absence of serum HCV RNA 24 weeks after treatment was completed. Secondary end points were normalization
of the serum alanine aminotransferase concentration and histologic improvement. The degree of hepatic inflammation and fibrosis was graded with a modified Knodell Histologic Activity
Index.20 The inflammation score was obtained by combining the
scores for the first three components of this index: portal,
periportal, and lobular inflammation. The scores could range
from 0 to 18, with higher scores indicating more severe abnormalities. The degree of fibrosis was graded as 0, no fibrosis;
1, portal fibrosis; 3, bridging fibrosis; or 4, cirrhosis. Histologic
improvement was defined as a decrease of at least two points in
the inflammation score, as compared with the score for the pretreatment biopsy specimen. The biochemical response and the
sustained combined biochemical and virologic response were also
assessed.1

The base-line characteristics of the patients in the
four groups were similar (Table 1). The proportion
of patients with HCV genotype 1 (72 percent) was
similar to the proportions in prior reports from the
United States.23,24

TABLE 2. VIROLOGIC

AND

Virologic Response

At the end of follow-up, the rates of virologic response were higher among the patients who had been
treated with interferon and ribavirin for 24 weeks
(31 percent) or 48 weeks (38 percent) than among
those who had received interferon alone for 48
weeks (13 percent, P<0.001) (Table 2). Increasing
the duration of combination therapy from 24 weeks

INTERFERON
24

Biochemical response
End of treatment
No. with response/
total no. treated
Percent (95% CI)
End of follow-up
No. with response/
total no. treated
Percent (95% CI)

RESULTS

BIOCHEMICAL RESPONSES
AND FOLLOW-UP.*

RESPONSE

Virologic response
End of treatment
No. with response/
total no. treated
Percent (95% CI)
End of follow-up
No. with response/
total no. treated
Percent (95% CI)

The study was designed to have 220 patients per group in order
to have a power of 89 percent to detect a difference of 15 percentage points between the rates of sustained virologic response
(30 percent vs. 45 percent), at a 5 percent level of significance
(with two-sided tests). The treatment responses were compared
with the use of Fisher’s exact test.21 Changes in the liver-biopsy
score within each group were compared with the use of Student’s
t-tests.21 The relation between pretreatment variables and treatment response was examined by stepwise logistic-regression analysis.22 All P values are two-tailed.

WK

AT THE

END

OF

INTERFERON
48

WK

24

TREATMENT

AND

RIBAVIRIN
48

WK

WK

66/231

54/225

121/228

115/228

29 (23–34)

24 (18–30)

53 (47–60)†

50 (44–57)†

13/231

29/225

70/228

87/228

6 (3–9)

13 (9–17)

31 (25–37)†

38 (32–45)†‡

56/231

62/225

133/228

149/228

24 (19–30)

28 (22–33)

58 (52–65)†

65 (54–67)†

25/231

35/225

72/228

83/228

11 (7–15)

16 (11–20)

32 (25–38)†

36 (30–43)†

*A virologic response was defined as the absence of serum HCV RNA (limit of detection, 100
copies per milliliter), and a biochemical response was defined as a normalization of the serum alanine
aminotransferase concentration. Responses were assessed in the last week of treatment and 24 weeks
later. CI denotes confidence interval.
†P<0.001 for the comparison with either interferon group.
‡P=0.05 for the comparison with 24 weeks of interferon and ribavirin.
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to 48 weeks increased the rate of virologic response
from 31 percent to 38 percent (P=0.05). The rates
of response at the completion of 24 weeks of therapy
were almost twice as high in the combination-therapy
group as in the interferon-alone group (53 percent
vs. 29 percent, P<0.001), and the respective rates after 48 weeks of therapy were more than twice as
high (50 percent vs. 24 percent, P<0.001). Relapse
after therapy was less frequent with combination
therapy (42 percent at 24 weeks and 24 percent at
48 weeks) than with interferon alone (80 percent at
24 weeks and 46 percent at 48 weeks).
In patients who were treated with interferon
alone, viral clearance at week 4 was associated with
a sustained virologic response, as reported previously.25-27 However, among 51 of the 87 patients (59
percent) who were treated with combination therapy
for 48 weeks and who eventually had sustained responses, HCV RNA remained detectable in serum
until week 12 or 24 of therapy. Late viral clearance
with a subsequent sustained response was also observed in 50 percent of patients (35 of 70 patients)
who were treated with interferon and ribavirin for
24 weeks, 23 percent of those (3 of 13 patients) who
received interferon alone for 24 weeks, and 52 percent of those (15 of 29 patients) who received interferon alone for 48 weeks.

percent) than in the interferon group as a whole (39
of 60 patients, 65 percent).

Biochemical Response

VARIABLE

The rate of sustained biochemical response was
higher among patients who received interferon and ribavirin for 24 or 48 weeks than among those who
received interferon alone for 24 or 48 weeks (Table 2).
The combined rates of sustained biochemical and
virologic responses in the groups given interferon
and ribavirin were 26 percent (60 of 228 patients) in
the group treated for 24 weeks and 34 percent (77
of 228 patients) in the group treated for 48 weeks,
as compared with 5 percent (12 of 231 patients,
P<0.001) in the group treated with interferon for 24
weeks and 12 percent (27 of 225 patients, P<0.001)
in the group treated with interferon for 48 weeks.
Normalization of serum alanine aminotransferase
values was associated with undetectable levels of
serum HCV RNA in most patients who had sustained virologic responses. Of 199 patients who had
a sustained virologic response, 176 (88 percent) had
persistently normal serum alanine aminotransferase
concentrations. The mean (±SD) elevations of serum
alanine aminotransferase after therapy in the remaining 23 patients (12 percent) was 1.6±0.1 times the
upper limit of the normal value. Eighteen percent of
patients (39 of 215) with a sustained biochemical response had persistently detectable serum HCV RNA.
The proportion of patients who had sustained virologic responses among those with a sustained biochemical response was higher in the combinationtherapy group as a whole (137 of 155 patients, 88
1488 ·

Histologic Response

Pretreatment and post-treatment liver-biopsy specimens were available from 670 patients (73 percent).
Histologic improvement occurred in all four groups,
but it was more common in either combinationtherapy group than in the interferon group that was
treated for 48 weeks (P<0.001) (Table 3). The degree of histologic improvement, defined as a decrease in the inflammatory score of at least two
points, was greatest in the group given interferon
and ribavirin for 48 weeks. Of the 165 patients who
had a sustained virologic response and who had pretreatment and post-treatment biopsy specimens available, 142 (86 percent) had a decrease in hepatic inflammation regardless of the treatment regimen.
Inflammation also decreased in 194 of 497 patients
(39 percent) who had persistent viremia at followup. Treatment had no effect on fibrosis.

TABLE 3. RATES

OF

HISTOLOGIC RESPONSE.*

INTERFERON
24 WK
48 WK
(N=176) (N=158)

Change in inflammation score†
All patients
Percent with improvement
Mean change
Patients with a response
Percent with improvement
Mean change
Patients with a relapse or no
response
Percent with improvement
Mean change
Change in fibrosis score¶
All patients
Percent with improvement
Mean change
Patients with a response
Percent with improvement
Mean change
Patients with a relapse or no
response
Percent with improvement
Mean change

INTERFERON
RIBAVIRIN

AND

24 WK
48 WK
(N=179) (N=157)

44
¡0.6

41
¡1.0

57
¡1.8‡

61
¡2.4§

89
¡3.8

78
¡5.2

88
¡4.4

86
¡4.5

41
¡0.4

35
¡0.3

41
¡0.6

39
¡0.5

11
0.1

17
¡0.1

16
0.0

14
0.0

11
¡0.2

26
¡0.2

24
¡0.2

16
¡0.1

11
0.1

16
0.0

12
0.2

12
0.2

*The numbers of patients are the numbers with pretreatment and posttreatment biopsy specimens.
†Scores could range from 0 to 18, with higher scores indicating more
severe abnormalities. Improvement was defined as a decrease in the inflammation score of at least two points, no change as an increase or decrease
of one point, and worsening as an increase of at least two points.
‡P=0.005 for the comparison with 48 weeks of treatment with interferon alone.
§P<0.001 for the comparison with 48 weeks of treatment with interferon alone.
¶Scores could range from 0 (no fibrosis) to 4 (cirrhosis). Improvement
was defined as a decrease of at least one point in the score.
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on alone for 48 weeks. The response of patients with
HCV genotypes other than 1 who were treated with
24 or 48 weeks of combination therapy were similar
irrespective of the base-line viral load, whereas the
response of patients with HCV genotype 1 and high
pretreatment viral loads was better among those
who received 48 weeks of combination therapy than
among those who received 24 weeks of therapy.
Stepwise logistic-regression analyses revealed that
greater efficacy was associated with HCV genotypes
other than 1 (P<0.001), a base-line viral load of
2¬106 copies per milliliter or less (P<0.001), the absence of cirrhosis at base line (P=0.04), and female
sex (P=0.05), in addition to combination treatment
(P<0.001) and 48 weeks of therapy (P=0.002).

Variables Associated with a Response

Treatment with interferon and ribavirin was the
strongest predictor of a response. Sustained virologic response was unrelated to age, sex, body weight,
or the estimated duration of disease. The response
rates for pretreatment variables known to influence
the response to treatment are shown in Table 4.
Among patients with HCV genotype 1 infection
who were treated for 48 weeks, the rate of sustained
response for patients who were treated with interferon and ribavirin was four times as high as that in patients who were treated with interferon alone for 48
weeks. Among patients with this genotype, 48 weeks
of combination therapy was more beneficial than 24
weeks of combination therapy (46 of 166 patients
[28 percent] had a response, as compared with 26
of 164 patients [16 percent]; P=0.01). The response
rates for patients with HCV genotype 1a infections
and those with genotype 1b infections were similar.
Among patients with other HCV genotypes who
were treated with combination therapy, the response
rates did not vary significantly as a function of the
duration of therapy. The results in patients with
HCV genotype 2 were similar to those in patients
with HCV genotype 3.
Regardless of the viral load at base line or the
presence of cirrhosis or bridging fibrosis at base line,
the response was better in patients who were treated
with interferon and ribavirin. Among patients with
a high viral load or fibrosis at base line, the response
rates were two to five times as high in those who were
treated with interferon and ribavirin for either 24 or
48 weeks as in those who were treated with interfer-

TABLE 4. RATES

OF

Safety

Hemoglobin concentrations decreased to less
than 10 g per deciliter, necessitating a reduction in
the dose of ribavirin, in 8 percent of the patients
who were treated with combination therapy (Table
5). The mean maximal decrease from base line was
3.1 g per deciliter (range of changes, ¡7.0 to +0.2)
after four weeks of therapy, and this was associated
with compensatory reticulocytosis. A reduction in the
dose resulted in an increase in hemoglobin concentrations of 1 to 1.5 g per deciliter, and the concentrations were subsequently stable throughout treatment.
Both hemoglobin concentrations and reticulocyte
counts returned to base line within 4 to 8 weeks after treatment was discontinued at 24 or 48 weeks.
The longer duration of therapy was not associated
with a significantly higher incidence of reductions in

SUSTAINED VIROLOGIC RESPONSE ACCORDING
AND TREATMENT GROUP.

VARIABLE

NO. OF
PATIENTS

TO

INTERFERON
24

WK

PRETREATMENT VARIABLES

INTERFERON
48

WK

24

AND

WK

RIBAVIRIN
48

WK

no./total no. of patients (%)

Genotype
1
Other
Base-line serum HCV RNA level
>2¬106 copies/ml
«2¬106 copies/ml
Degree of fibrosis at base line¶
Cirrhosis or bridging fibrosis
Minimal or no fibrosis

659
253

3/167 (2)
10/64 (16)

11/162 (7)
18/63 (29)

26/164 (16)* 46/166 (28)†
44/64 (69)† 41/61 (66)†

637
275

6/157 (4)
7/74 (9)

11/162 (7)
18/63 (29)

44/166 (27)† 54/152 (36)†
26/62 (42)‡ 33/76 (43)§

250
608

3/65 (5)
7/154 (5)

9/71 (13)
18/136 (13)

17/59 (29)* 21/55 (38)†
51/159 (32)† 62/159 (39)†

*P=0.01 for the comparison with interferon alone for 48 weeks.
†P<0.001 for the comparison with interferon alone for 48 weeks.
‡P=0.06 for the comparison with interferon alone for 48 weeks.
§P=0.04 for the comparison with interferon alone for 48 weeks.
¶Fibrosis was defined as a score of 3, and cirrhosis as a score of 4. The degree of fibrosis could not be adequately
evaluated in the pretreatment biopsy specimens of 54 patients.
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TABLE 5. RATES OF DISCONTINUATION OF TREATMENT,
DOSE REDUCTIONS, AND OTHER ADVERSE EVENTS
DURING TREATMENT.*

ADVERSE EVENT

INTERFERON
RIBAVIRIN

INTERFERON

AND

24 WK
48 WK
(N=231) (N=225)

24 WK
48 WK
(N=228) (N=228)

percent

Discontinuation of treatment for
any severe event
Dose reduction
Due to anemia†
Due to other adverse events‡
Influenza-like symptoms
Headache
Fatigue
Malaise
Myalgia
Arthralgia
Musculoskeletal pain
Fever
Gastrointestinal symptoms
Anorexia
Dyspepsia
Vomiting
Nausea
Diarrhea
Abdominal pain
Psychiatric symptoms
Anxiety
Impaired concentration
Depression
Emotional lability
Insomnia
Irritability
Respiratory tract symptoms
Cough
Dyspnea
Pharyngitis
Sinusitis
Dermatologic symptoms
Alopecia
Pruritus
Rash
Dry skin
Inflammation at injection site

9

14

8

21

0
12

0
9

7
13

9
17

63
62
7
57
27
26
35

67
72
5
63
36
32
40

63
68
4
61
30
20
37

66
70
11
64
33
28
41

16
6
10
35
22
17

19
9
13
33
26
20

27
14
11
38
18
15

25
16
9
46
22
14

9
14
25
6
27
19

13
14
37
8
30
27

10
11
32
7
39
23

18
14
36
11
39
32

5
9
9
7

9
10
10
14

15
19
11
9

14
18
20
10

27
9
9
4
10

28
8
8
8
14

28
21
20
8
13

32
19
28
15
12

*Only events that occurred in at least 10 percent of patients are included.
†The daily dose of ribavirin was reduced to 600 mg for patients with hemoglobin values below 10 g per deciliter, and treatment with ribavirin was
discontinued in patients with hemoglobin values below 8.5 g per deciliter.
‡In the case of other severe events, the dose of interferon was decreased
to 1.5 million units three times a week and the dose of ribavirin was decreased to 600 mg per day.

the dose of ribavirin due to anemia. Discontinuation
of therapy and transfusion were necessary in one patient with a hemoglobin concentration of less than
10 g per deciliter. Reductions in the dose of ribavirin
and subsequent completion of treatment did not affect the rate of sustained response. Leukocyte counts
decreased in all groups during therapy, but the mean
value remained within the normal range. The mean
platelet counts were similar at base line and during
1490 ·

therapy, remaining above 100¬103 per cubic millimeter in 95 to 98 percent of all patients.
Dyspnea, pharyngitis, pruritus, rash, nausea, insomnia, and anorexia were more common with combination therapy than with interferon alone (Table 5).
The incidence of side effects was higher after 48 weeks
of treatment than after 24 weeks of treatment, regardless of the type of therapy.
The drug doses were reduced because of adverse
events other than anemia in 13 percent of patients
who were given interferon and ribavirin for 24 weeks
and in 17 percent of those who were treated for 48
weeks. Among the patients who were given interferon alone, the dose was reduced in 12 percent of
those who were treated for 24 weeks and in 9 percent of those who were treated for 48 weeks. The
most frequent reason for the discontinuation of therapy in all groups was emotional disturbance — mainly
depression; the frequency of cessation of treatment
for depression ranged from 2 to 9 percent in the
four groups.
DISCUSSION

The currently approved initial therapy for patients
with chronic HCV infection consists of treatment
with interferon for at least 48 weeks. The rates of
sustained virologic response with this regimen are
approximately 15 to 20 percent.7-12 Our results confirm this low response rate.
We found that combination therapy with interferon and ribavirin for either 24 or 48 weeks was superior to therapy with interferon alone with respect
to virologic, biochemical, and histologic end points.
The higher rates of sustained virologic response
were the result of higher rates of response at the end
of treatment and, subsequently, lower rates of relapse. Recent reports suggest that similar sustained
virologic responses are usually long-lasting (5 to 10
years) and are accompanied by progressive histologic improvement.28,29 In our study, late clearance of
HCV RNA from serum during combination therapy
was also frequently associated with a sustained response. This phenomenon is uncommon in patients
who are treated with interferon alone, which suggests
that stopping therapy at week 12 because of persistent viremia, as recently suggested,1,18,30 may not be
appropriate in the case of therapy with interferon and
ribavirin.
The beneficial effect of combination therapy also
extended to subgroups of patients in whom treatment
has historically been unsuccessful, such as patients
with HCV genotype 1 infection, high pretreatment
viral burdens, or advanced fibrosis or cirrhosis. Approximately 70 percent of U.S. patients with chronic
HCV have genotype 1 infection, and such patients
derived the greatest benefit from combination therapy for 48 weeks, suggesting that HCV genotyping
should be considered before treatment is initiated.
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Ribavirin, a synthetic guanosine analogue, has actions in vitro against a range of RNA and DNA viruses.31 When given alone to patients with chronic
hepatitis C, ribavirin decreases serum aminotransferase concentrations but has no antiviral effect.32-34 Ribavirin has been postulated to inhibit viral-dependent RNA polymerase, the capping structure of viral
messenger RNA, and inosine monophosphate dehydrogenase.31 Other immunomodulatory actions may
also contribute to the drug’s beneficial effects.35 Despite these potential actions, the exact mechanism responsible for the improved response that occurs when
ribavirin is combined with interferon is unknown.
Combination therapy was relatively safe, but modifications in the dose and discontinuation of treatment
were required more often in patients who received
interferon and ribavirin than in those who were
treated with interferon alone. Reversible, hemolytic
anemia due to ribavirin occurred, as has been previously reported when this drug was given alone.32-34
Patients who are treated with ribavirin should therefore be monitored closely (hemoglobin should be
measured two and four weeks after therapy is begun
and then as clinically indicated). The symptoms related to treatment with interferon and ribavirin have
been reported previously, and there were no synergistic effects. Cough, pruritus, rash, and insomnia, all
of which have been associated with the use of other,
similar nucleoside analogues, were more common in
the patients who received combination therapy.
In summary, in patients with chronic hepatitis C,
therapy with interferon and ribavirin is more effective than interferon alone in inducing virologic and
histologic improvement, and the combination may
therefore be indicated as initial therapy in such patients.
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